Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BLRX
stocks logo

BLRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
492.00K
-95.81%
--
--
617.00K
+141.96%
--
--
652.00K
+114.47%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for BioLineRx Ltd. (BLRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -11.25%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-11.25%
In Past 3 Month
Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.257
sliders
Low
12.00
Averages
12.00
High
12.00
Current: 3.257
sliders
Low
12.00
Averages
12.00
High
12.00
Jones Trading
Justin Walsh
Strong Buy
to
Hold
Downgrades
n/a
2025-04-02
Reason
Jones Trading
Justin Walsh
Price Target
n/a
2025-04-02
Downgrades
Strong Buy
to
Hold
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$9 → $26
2025-03-31
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$9 → $26
2025-03-31
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for BioLine RX Ltd (BLRX.O) is -1.57, compared to its 5-year average forward P/E of -1.56. For a more detailed relative valuation and DCF analysis to assess BioLine RX Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.56
Current PE
-1.57
Overvalued PE
-0.07
Undervalued PE
-3.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.20
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.08
Undervalued EV/EBITDA
-2.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.99
Current PS
5.93
Overvalued PS
56.05
Undervalued PS
-30.08
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BLRX News & Events

Events Timeline

(ET)
2025-11-24
07:04:33
BioLineRx Announces Q3 EPS of 0c, Unchanged from Last Year
select
2025-09-29 (ET)
2025-09-29
07:06:08
BioLineRx and Hemispherian AS Form Joint Venture for GLIX1 Development
select
2025-08-14 (ET)
2025-08-14
07:03:01
BioLineRx reports Q2 EPS 0c vs. 0c last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
11-24TipRanks
Today's Options Volatility and Implied Earnings Changes - November 24, 2025

  • Earnings Reports Today: Major companies such as Agilent, Zoom Video Communications, and Semtech are set to report their earnings today, with expected significant stock movements based on options prices.

  • Options Activity Insights: Investors are closely monitoring options activity prior to earnings announcements, as it can provide insights into potential stock price movements following the reports.

  • Implied Moves Before Market Open: Companies like Bioline RX and Lexinfintech are expected to have substantial implied moves of +/- 187.69% and +/- 30.33%, respectively, before the market opens.

  • Implied Moves After Market Close: Other companies reporting after market close, including Agilent and Zoom, have implied moves ranging from +/- 8.20% to +/- 29.35%, indicating varying levels of expected volatility.

[object Object]
Preview
8.0
11-24TipRanks
Options Volatility and Projected Earnings Changes for the Week of November 24 – November 26, 2025

  • Upcoming Earnings Reports: Major companies such as Alibaba, Nio, Zoom, Dell, and Li Auto are set to report their earnings this week.

  • Options Volatility: The article discusses how options volatility increases before earnings announcements due to uncertainty, leading to higher option premiums.

  • Volatility Crush: After earnings are announced, the uncertainty resolves, causing a significant decrease in option premiums, known as the volatility crush.

  • Expected Stock Moves: The expected stock price movements for various companies are provided, with percentages indicating potential volatility around their earnings announcements.

[object Object]
Preview
9.5
11-24SeekingAlpha
BioLineRx Reports GAAP EPS of $0.00, Exceeding Expectations by $0.54; Revenue of $0.43M Falls Short by $0.24M

  • Earnings Performance: BioLineRx reported a Q3 GAAP EPS of $0.00, exceeding expectations by $0.54.

  • Revenue Decline: The company generated revenue of $0.43 million, which represents a 91.3% year-over-year decrease and fell short of estimates by $0.24 million.

  • Cash Position: As of September 30, 2025, BioLineRx has $25.2 million on its balance sheet, indicating a stable cash runway into the first half of 2027.

  • Additional Resources: The press release includes links to BioLineRx's investor call transcript, historical earnings data, and financial information.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BioLine RX Ltd (BLRX) stock price today?

The current price of BLRX is 3.257 USD — it has increased 1.15 % in the last trading day.

arrow icon

What is BioLine RX Ltd (BLRX)'s business?

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

arrow icon

What is the price predicton of BLRX Stock?

Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BioLine RX Ltd (BLRX)'s revenue for the last quarter?

BioLine RX Ltd revenue for the last quarter amounts to 427.00K USD, decreased -91.36 % YoY.

arrow icon

What is BioLine RX Ltd (BLRX)'s earnings per share (EPS) for the last quarter?

BioLine RX Ltd. EPS for the last quarter amounts to -0.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for BioLine RX Ltd (BLRX)'s fundamentals?

The market is revising No Change the revenue expectations for BioLineRx Ltd. (BLRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -11.25%.
arrow icon

How many employees does BioLine RX Ltd (BLRX). have?

BioLine RX Ltd (BLRX) has 28 emplpoyees as of December 05 2025.

arrow icon

What is BioLine RX Ltd (BLRX) market cap?

Today BLRX has the market capitalization of 14.17M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free